SA
LCTX logo
Lineage Cell Therapeutics, Inc.(LCTX)
Closing price · checked 9:42 PM ETAbout this dataData status
$0.77▼-0.05 (-5.87%)
Extended:$0.83+0.05 (+7.03%)· 9:42 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Consensus

Buy4.00 / 53 ratings · Buy 3

Price vs analyst targets

Revenue and EPS estimates

ReportedConsensus estimates
Fiscal periodFY2023Dec '23FY2024Dec '24FY2025Dec '25FY2026Dec '26FY2027Dec '27FY2028Dec '28FY2029Dec '29FY2030Dec '30
Revenue (M)8.99.514.59.724.934.789.0528.9
Growth YoY−39.2%+6.6%+52.6%−33.2%+156.2%+39.3%+156.9%+493.9%
High estimate–––20.955.1107.0225.51,339.3
Low estimate–––4.15.63.021.9130.2
Analysts–––45643
EPS, adjusted−0.13−0.10−0.16−0.04−0.06−0.050.061.13
Growth YoYn/mn/mn/mn/mn/mn/mn/m+1859.4%
High estimate–––−0.010.130.200.173.37
Low estimate–––−0.06−0.19−0.720.000.02
Analysts–––44632

Consensus mean of analyst estimates. EPS is adjusted (street) EPS, the basis analysts forecast; annual actuals are the sum of the four reported quarters. Growth compares with the same period a year earlier; n/m where the prior period was a loss.

Brokers

3 firms active in the last 12 months
FirmAnalystRatingPrev ratingTargetPrev targetChgUpsideDate
HC Wainwright & Co.–BuyBuy––––Jul 14
D. Boral Capital–BuyBuy––––May 4
B. Riley Securities–BuyBuy––––Mar 25

Latest analyst action Page refreshed hourly; analyst feeds refreshed dailyAbout this data

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.